First use of imlifidase desensitization in a highly sensitized lung transplant candidate: a case report

Abstract

Lung transplant candidates who are highly sensitized against human leucocyte antigen present an ongoing challenge with regards to finding immunologically acceptable donors. Desensitization strategies aimed at reducing preformed donor-specific antibodies have a number of limitations. Imlifidase, an IgG-degrading enzyme derived from Streptococcus pyogenes, is a novel agent that has been used to convert positive crossmatches to negative in kidney transplant candidates, allowing transplantation to occur. We present the first case of imlifidase use for antibody depletion in a highly sensitized lung transplant candidate who went on to undergo a successful bilateral lung transplant.

Keywords: clinical research/practice; crossmatch; desensitization; histocompatibility; immunosuppressant–other; immunosuppression/immune modulation; lung transplantation/pulmonology; panel reactive antibody (PRA); rejection: antibody-mediated (ABMR).